Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "We expect PDS will fund its operations through licensing revenue."

<not to fund PDS' operations sounds like they are expecting incoming revenues SOON.>

<On October 7, 2011 PDS’ cash balance is $79,130>.

Very Soon!!

Opty

Share
New Message
Please login to post a reply